Financial year 2018 – ARCONDIS Group doubles its revenue in Germany
Basel/Frankfurt/Munich, March, 2019
ARCONDIS AG, too, successfully achieved solid growth from an already high level. With more than a hundred employees, the Swiss parent company generated a revenue of 19.5 million Swiss Francs in 2018, which corresponds to a growth rate of 4%. Strategic consulting assignments regarding the digital transformation and regulatory requirements, topics that have played an established role with major life sciences companies for many years, are becoming increasingly important. Besides the medical device regulation (MDR) and the serialization requirements laid out in the falsified medicines directive (FMD), the data protection requirements of the EU GDPR were particularly relevant to the life sciences industry last year.
“In 2019, we will focus on ensuring that our customers benefit from the advantages offered by digitalization. We use the umbrella term Life Sciences 4.1 to describe the corresponding technologies and measures in a highly customer-specific way that take compliance aspects into account,” Christian Baumgartner, Founder and President of the Supervisory Board of the ARCONDIS Group, commented.